World Journal of Nuclear Medicine最新文献

{"title":"Discordance of Dual-Tracer PET/CT with Histopathology in a Grade I Pancreatic Neuroendocrine Tumor: A Diagnostic Conundrum.","authors":"Sarina Shah, Keerti Sitani, Gauri Deshpande, Sandip Basu","doi":"10.1055/s-0045-1812058","DOIUrl":"10.1055/s-0045-1812058","url":null,"abstract":"<p><strong>Objectives: </strong>Neuro endocrine tumors (NETs) demonstrate complex biology where imaging and histology can at times show discordance in a real-world scenario.</p><p><strong>Materials and methods: </strong>We herein present a patient of grade I pancreatic NET showing atypical low somatostatin receptor expression on ⁶⁸ Ga-DOTATATE PET/CT (positron emission tomography/computed tomography) but intense fluorine-18-deoxyglucose ( ¹⁸ FDG) avidity, and when interpreted together, these findings showed discordance with histopathology.</p><p><strong>Results: </strong>The case highlights the crucial role of dual-tracer PET/CT in navigating the tumor biology and landscape of NET and the need for novel strategies to complement traditional histopathology that would enable better therapeutic decision-making.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"25 1","pages":"70-74"},"PeriodicalIF":1.0,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13134918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Huntington's Disease with Parkinson-Like Symptoms and Abnormal [ ¹²³ I] Ioflupane SPECT-CT (DaTs): A Case Report and Literature Review.","authors":"Sarah Amro, Chamani Punchihewa, Edina Bravo, Sabina Dizdarevic","doi":"10.1055/s-0045-1812051","DOIUrl":"10.1055/s-0045-1812051","url":null,"abstract":"<p><p>Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by an unstable expansion of CAG trinucleotide repeats that lead to progressive degeneration of postsynaptic striatal medium-spiny GABAergic neurons. We report a case of abnormal [ ¹²³ I] Ioflupane single-photon emission computed tomography/computed tomography (DaTSCAN) and a subsequent genetic test confirming HD. A 68-year-old man presented with progressive memory difficulties, auditory hallucinations, nightmares, suicidal thoughts, low mood, and involuntary limb movements. DaTSCAN showed borderline reduced putaminal binding ratios bilaterally, more prominent on the left side, and a low putamen-to-caudate ratio suggesting degenerative parkinsonism. Genetic testing revealed one pathogenic expansion (40/17 CAG repeats), confirming HD. Postsynaptic dopaminergic involvement has previously been documented in postmortem studies. However, an emerging in vivo research also suggests presynaptic dopaminergic involvement. While genetic testing remains the gold standard for diagnosis of HD, DaTSCAN may play a role in assessing dopamine transporter activity and tracking the progression of neurodegeneration in HD.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"25 1","pages":"46-50"},"PeriodicalIF":1.0,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13134912/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving Equitable Cancer Treatment in Australia: The Case for Theranostics in the Northern Territory.","authors":"Joshua J Morigi, Suzanne McGavin","doi":"10.1055/s-0045-1812052","DOIUrl":"10.1055/s-0045-1812052","url":null,"abstract":"<p><p>The Northern Territory (NT) of Australia is a large, low-density territory with the highest percentage of First Nations people in Australia, many of whom live remotely and encounter difficulties and barriers to accessing services. This determines significant gap in healthcare delivery inclusive of Nuclear Medicine and theranostic therapy services. In particular, no theranostic service for cancer patients is currently available in the NT. A narrative retrospective analysis of the provision of nuclear medicine services within the NT at the Royal Darwin Hospital was undertaken to determine the suitability and relevance of the establishment of a new theranostic service within the NT, catered to the specific needs of the local population and in particular of the large proportion of First Nations Patients that are likely to benefit from the local service. Building on the preexisting structure of Nuclear Medicine and PET, inclusive of a comprehensive facility with local production of radiopharmaceuticals, it is expected that the implementation of a theranostic service within the NT will have a high intake and a flow-down positive effect on cancer care within the NT. The implementation of cultural safety principles within the department is embedded in our model of service provision and will further be implemented in the theranostic service delivery. A theranostic service within the NT will prove beneficial to the NT population and sustainable financially. Principles of Cultural safety are paramount to service provision in the NT, and will hopefully contribute to enhancing the experience and improving the outcomes for First Nations patients.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"24 3","pages":"253-258"},"PeriodicalIF":0.9,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12602072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145496941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IgG4-Related Disease and Synchronous Marginal Zone Lymphoma Evaluated by 99mTc-iFAP SPECT/CT and [ ¹⁸ F]-FDG PET/CT: A Case Report.","authors":"Joel E Vargas-Ahumada, Miguel A Corza-Ayala, Rodrigo Hernández-Ramírez, Myrna A Luna-Gutierrez","doi":"10.1055/s-0045-1810609","DOIUrl":"10.1055/s-0045-1810609","url":null,"abstract":"<p><strong>Background: </strong>IgG4-related disease (IgG4-RD) is a chronic fibro-inflammatory condition that can mimic malignancy due to its tumorous lesions. Marginal zone lymphoma (MZL), a low-grade B cell lymphoma, may occasionally arise in the context of chronic immune stimulation. The synchronous occurrence of IgG4-RD and MZL is rare and diagnostically challenging.</p><p><strong>Case report: </strong>We report the case of a 39-year-old male with right hemiplegia and aphasia, initially suspected to have a meningioma based on magnetic resonance imaging (MRI) findings. Histopathology following surgical resection revealed features consistent with IgG4-RD. Subsequently, [ ¹⁸ F]-FDG PET/CT ([ ¹⁸ F]-fluorodeoxyglucose positron emission tomography/computed tomography) demonstrated a metabolically inactive extra-axial supratentorial lesion, as well as a hypermetabolic triangular consolidation in the left lower lung lobe. Lung biopsy confirmed bronchus-associated lymphoid tissue MZL. Immunohistochemistry supported the dual diagnosis. Complementary 99mTc-iFAP SPECT/CT (single photon emission computed tomography/CT) demonstrated focal uptake in the central nervous system lesion but not in the pulmonary lesion. Multimodal image fusion with brain MRI facilitated precise anatomical and functional correlation.</p><p><strong>Discussion: </strong>The coexistence of IgG4-RD and MZL raises important considerations regarding shared immunopathogenic mechanisms. Dual molecular imaging with FDG and FAPI (fibroblast activating protein inhibitor)-based radiotracers proved essential in discriminating between inflammatory and neoplastic components of disease, enabling accurate diagnosis and guiding appropriate management.</p><p><strong>Conclusion: </strong>This case highlights the value of [ ¹⁸ F]-FDG PET/CT and 99mTc-iFAP SPECT/CT in the evaluation of complex systemic diseases. fibroblast activation protein-targeted imaging may play a key role in the diagnostic workup of IgG4-RD and in distinguishing it from coexisting lymphoproliferative disorders.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"25 1","pages":"65-69"},"PeriodicalIF":1.0,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13134917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Diagnostic Quandary of Primary Renal Ewing's Sarcoma on ¹⁸ F-FDG PET/CT Scan: A Case Report with a Thorough Review of Literature.","authors":"Anuradha Pandit, Shaivy Malik, Charanjeet Ahluwalia","doi":"10.1055/s-0045-1810114","DOIUrl":"10.1055/s-0045-1810114","url":null,"abstract":"<p><p>Ewing's sarcoma (EWS) of the kidney is an extremely rare and aggressive malignancy, accounting for less than 1% of renal tumors. This report presents a 42-year-old male who initially presented with hematuria and intermittent fever, with imaging studies suggesting a renal cell carcinoma (RCC). However, histopathological and immunohistochemical analysis, including CD99 positivity and NKX2.2 nuclear expression, confirmed the diagnosis of primary renal EWS. The patient was promptly started on neoadjuvant chemotherapy (VAC + IE [vincristine, adriamycin, cyclophosphamide, ifosfamide, and etoposide]), which he tolerated well without significant adverse effects. Given its nonspecific clinical and ¹⁸ F-fluorodeoxyglucose positron emission tomography/computed tomography scan presentation, the case highlights the diagnostic challenges in distinguishing renal EWS from more common renal neoplasms such as RCC. Early diagnosis through histopathology and immunohistochemistry is crucial for guiding appropriate management. Given the aggressive nature of renal EWS, a multimodal treatment approach involving chemotherapy followed by radical nephrectomy is essential for improving prognosis. This case sheds light on the importance of considering renal EWS in the differential diagnosis of renal masses and emphasizes the role of early intervention in enhancing survival outcomes.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"25 1","pages":"56-64"},"PeriodicalIF":1.0,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13134906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147820703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced T-cell Lymphoma with Penile Involvement Revealed by ¹⁸ F-FDG PET/CT: A Rare Presentation.","authors":"Yassir Benameur, Adnane Hammani, Jaafar El Bakkali, Abderrahim Doudouh","doi":"10.1055/s-0045-1810100","DOIUrl":"10.1055/s-0045-1810100","url":null,"abstract":"<p><p>T-cell lymphomas are rare malignancies that frequently involve extranodal sites, but penile localization remains exceedingly uncommon. We report the case of a 21-year-old man diagnosed with cutaneous T-cell lymphoma who underwent 18F-fluorodeoxyglucose positron emission tomography/computed tomography ( ¹⁸ F-FDG PET/CT) for initial staging. The scan revealed widespread nodal and extranodal disease, including unexpected intense fluorodeoxyglucose uptake in the corpora cavernosa, in the absence of penile symptoms. Penile involvement in lymphoma, whether primary or secondary, Hodgkin or non-Hodgkin, is exceptionally rare, with very few cases reported-most involving B cell histologies. This finding underscores the utility of PET/CT in identifying clinically silent and atypical disease sites in aggressive lymphomas such as peripheral T-cell lymphoma. The extent of dissemination, including renal, adrenal, bone marrow, and penile involvement, reflects a high tumor burden and portends a poor prognosis. Early recognition of such patterns through PET/CT is essential for appropriate therapeutic planning and may impact patient outcomes.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"25 2","pages":"172-174"},"PeriodicalIF":1.0,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13327779/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148377370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A New Labeling Method of ^99m Tc-PSMA-HBED-CC.","authors":"Benchamat Phromphao, Shuichi Shiratori","doi":"10.1055/s-0045-1809921","DOIUrl":"10.1055/s-0045-1809921","url":null,"abstract":"<p><strong>Objective: </strong>⁶⁸ Ga-PSMA-HBED-CC ( ⁶⁸ Ga-PSMA-11) was approved by the U.S. Food and Drug Administration as the first prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging drug for patients with prostate cancer. However, the utility of ⁶⁸ Ga-PSMA-HBED-CC may be limited due to PET/CT or PET/MR accessibility and ⁶⁸ GaCl ₃ availability produced from ⁶⁸ Ge/ ⁶⁸ Ga generator or cyclotron. Thus, in-house preparation of ^99m Tc-PSMA-HBED-CC was developed as an alternative to ⁶⁸ Ga-PSMA-HBED-CC to be ubiquitous and affordable in the worldwide population.</p><p><strong>Methods: </strong>A solution of ^99m Tc-pertechnetate was added to PSMA-HBED-CC and 4% SnCl ₂ ·2H ₂ O in a 10-mL sterile vial. The mixture was heated at 100°C for 15 minutes and then allowed to cool to room temperature. Labeling conditions were optimized to maximize the radiochemical yield of ^99m Tc-PSMA-HBED-CC. The chelation completeness was monitored using instant thin layer chromatography, and the stability of ^99m Tc-PSMA-HBED-CC was subsequently evaluated.</p><p><strong>Results: </strong>The radiolabeling of ^99m Tc-PSMA-HBED-CC was successful using the appropriate amount of 10 µg PSMA-HBED-CC 3 µg SnCl ₂ ·2H ₂ O and ^99m Tc-pertechnetate 370 MBq at 100°C for 15 minutes, yielded the best result in high radiochemical yield (71.49 ± 2.42%), radiochemical purity (98.29 ± 2.65%), and specific activity of 37.84 ± 1.47 GBq/µmol. ^99m Tc-PSMA-HBED-CC is stable with radiochemical purity of more than 95% within 4 hours at room temperature.</p><p><strong>Conclusion: </strong>A new labeling method of ^99m Tc-PSMA-HBED-CC was developed. Quality control parameters of ^99m Tc-PSMA-HBED-CC met the criteria in accordance with the European Pharmacopoeia.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"24 4","pages":"319-324"},"PeriodicalIF":0.9,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12774520/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145918687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted Alpha Radiopharmaceutical Therapy and Key Considerations for Nuclear Medicine Technologists.","authors":"Julie Bolin, Daryn Groves","doi":"10.1055/s-0045-1809342","DOIUrl":"10.1055/s-0045-1809342","url":null,"abstract":"<p><p>The use of radionuclides for targeted radiopharmaceutical therapy (RPT) is a rapidly evolving field in nuclear medicine and oncology. With the integration of imaging and therapy, therapeutic nuclear medicine has made remarkable progress in recent years. One particularly promising area of research is the use of α-emitting radionuclides, which possess unique physical properties that provide notable advantages, including the ability to target single tumor cells with high precision. Although the only targeted α therapy (TAT) currently approved by the United States Food and Drug Administration is ²²³ Ra-dichloride for the treatment of castration-resistant prostate cancer with skeletal metastases, a search on clinicaltrials.gov yields a significant number of early- and late-stage clinical trials utilizing 223-Ra, 225-Ac, 211-At, 212-Pb, and 227-Th are in progress, indicating that more TATs are on the horizon. As the prevalence of use for TAT increases, it is important to consider the logistics of TAT administration and the requirements for radiation safety and patient discharge. This review aims to provide a comprehensive overview of the advancements, relevant clinical trials, and logistical considerations associated with targeted α RPT in oncology.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"24 3","pages":"192-203"},"PeriodicalIF":1.0,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12602079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145496876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iodine-Negative Rare Gluteal Muscle Metastasis of Papillary Thyroid Cancer: Detected by ⁶⁸ Ga-DOTATATE PET/MRI and ¹⁸ F-FDG PET/CT.","authors":"Seckin Bilgic, Irem Koroglu, M Sait Sager, Kerim Sonmezoglu","doi":"10.1055/s-0045-1809423","DOIUrl":"10.1055/s-0045-1809423","url":null,"abstract":"<p><p>The case presents a 57-year-old male with metastatic papillary thyroid carcinoma (PTC) to the lymph nodes, lung, and mediastinum. Despite receiving multiple high-dose radioactive iodine (RAI) therapies, the patient's serum thyroglobulin levels continued to rise. The patient, who was unresponsive to RAI therapy, was being evaluated for suitability for ¹⁷⁷ Lu-DOTATATE therapy. Therefore, after the third high-dose treatment, simultaneous ⁶⁸ Ga-DOTATATE PET/MRI and ¹⁸ F FDG PET/CT imaging were performed, revealing a painless mass in the left gluteal region. The gluteal mass was excised, and histopathology confirmed it as metastatic PTC. Muscle metastases are extremely rare for PTC. This case exemplifies the different levels of tumoral affinity shown by aggressive variants of PTC across three distinct imaging modalities: ⁶⁸ Ga-DOTATATE PET/MRI, ¹⁸ F FDG PET/CT, and whole-body iodine scintigraphy.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"24 4","pages":"383-386"},"PeriodicalIF":0.9,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12774529/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145917477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute and Chronic Presentation of Melioidosis: ¹⁸ F-FDG PET/CT Case Series.","authors":"Harini Koorma, Mohan Roop Jayanthi, Haripriya Reddy Challa, Nagamani Chella, Suneetha Batchu","doi":"10.1055/s-0045-1809422","DOIUrl":"10.1055/s-0045-1809422","url":null,"abstract":"<p><p>Melioidosis is an infectious disease that is caused by a gram-negative bacillus, <i>Burkholderia pseudomallei</i> , which has been designated as a category B bioterrorism agent by the U.S. Centers for Disease Control and Prevention. Melioidosis manifests as a multi-system disorder. The effectiveness of ¹⁸ F-FDG PET/CT (18-fluorine-fluorodeoxyglucose positron emission tomography-computed tomography) in diagnosing or managing melioidosis is currently uncertain or not well-established. ¹⁸ F-FDG PET/CT is a useful tool in detecting the location and extent of abscess formation, assessing the organs involved, and detecting occult foci of infection, due to the multifocal nature of the disease. Herein, we present cases of two patients referred for a whole-body ¹⁸ F-FDG PET/CT scan with a history of pyrexia of unknown origin.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"24 4","pages":"377-382"},"PeriodicalIF":0.9,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12774528/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145918737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}